SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $120

Morgan Stanley maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $121 to $120.

Benzinga · 05/07/2020 12:54

Morgan Stanley maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $121 to $120.